Medicare Part B Preferred drug list — Aetna Assure Premier Plus (HMO D-SNP)

Some medically administered Part B drugs may have extra requirements or limits on coverage. These may include step therapy. This is when we require you to first try certain preferred drugs to treat your medical condition before covering another non-preferred drug.

For example, if drug A and drug B both treat your condition, we may prefer drug A, and require you to try it first. If drug A does not work for you, we will then cover drug B. The listed preferred products should be used first. An exception process is in place for specific cases that may call for a non-preferred product.

Drug classes with preferred products are listed below. For specific medical indications subject to step therapy, please see the corresponding clinical policy bulletin on the Aetna® website.

To find out more, go to **AetnaBetterHealth.com/NewJersey-hmosnp**. You can also call us at 1-844-362-0934 (TTY: 711), 8 a.m. to 8 p.m., 7 days a week.

Drug Class/Indication(s)	Non-Preferred Product(s)	Preferred Product(s)
Acromegaly	Signifor LAR Somavert	Sandostatin LAR Somatuline depot
Alpha 1 antitrypsin deficiency	Aralast NP Glassia Zemaira	Prolastin-C
Bone Resorption Inhibitors • Hypercalcemia of malignancy	Xgeva	Pamidronate Zoledronic acid
Botulinum ToxinsCervical dystoniaUpper limb spasticity	Botox Myobloc	Dysport Xeomin
Botulinum ToxinsBlepharospasmChronic sialorrhea		Xeomin
Botulinum Toxins • Lower limb spasticity		Dysport
 CSF — Leukocyte Growth Factors (filgrastim) Prevention of febrile neutropenia Symptomatic neutropenic disorder Harvesting of peripheral blood stem cells 	Granix Neupogen Nivestym Releuko	Zarxio

Proprietary

CSF — Leukocyte Growth Factors (pegfilgrastim) • Prevention of febrile neutropenia	Nyvepria Ziextenzo	Fulphila Neulasta Neulasta Onpro Udenyca
Erythropoiesis Stimulating AgentsAnemia due to chronic kidney diseaseAnemia due to chemotherapy	Epogen	Aranesp Procrit Retacrit
 Erythropoiesis Stimulating Agents Anemia due to Zidovudine use in HIV Transfusion reduction for select surgeries 		Procrit Retacrit
Gonadotropin-Releasing Hormone Agonists • Advanced prostate cancer	Lupron depot Trelstar Zoladex	Eligard
Gonadotropin-Releasing Hormone Antagonists • Advanced prostate cancer		Firmagon
Immunologics (B through B) • Ulcerative colitis	Inflectra Renflexis Stelara	Avsola Entyvio Remicade
Immunologics (B through B) • Crohn's disease		Entyvio
 Intravenous iron Iron deficiency anemia after intolerance or unsatisfactory response to oral iron 	Feraheme Injectafer Monoferric	Ferrlecit Sodium ferric gluconate Infed Venofer
 IVIG (intravenous immunoglobulin)* Primary immunodeficiency Idiopathic thrombocytopenia purpura Chronic inflammatory demyelinating polyneuropathy 	Asceniv Bivigam Flebogamma Gammagard Gammaked Gammaplex Gamunex-C Octagam Panzyga	Privigen

NJ-22-06-01 H6399_NR_30366_2022_C

 SCIG (subcutaneous immunoglobulin)* Primary immunodeficiency Chronic inflammatory demyelinating polyneuropathy *IVIG and SCIG are one category. Use either preferred product before a non-preferred IVIG or SCIG. 	Cutaquig Cuvitru Gammagard Gammaked Gamunex-C HyQvia Xembify Darzalex	Hizentra
Multiple myeloma	Darzalex Faspro Kyprolis	Velcade
Multiple Sclerosis Myelodysplastic syndrome	Lemtrada Dacogen Decitabine Vidaza	Tysabri Azacitidine
Oncology (Abraxane) • Non-small cell lung cancer	Abraxane Paclitaxel (protein bound)	Docetaxel Paclitaxel
Oncology (Herceptin) • Breast cancer	Herzuma Ogivri Ontruzant	Herceptin Herceptin Hylecta Kanjinti Trazimera
Oncology (Herceptin) • Gastrointestinal cancer		Herceptin Kanjinti Trazimera
Ophthalmic Disorders	Beovu Byooviz Eylea Lucentis Susvimo Vabysmo	Bevacizumab (Avastin)
Pulmonary Arterial Hypertension (Remodulin)	Remodulin	Generic treprostinil
Pulmonary Arterial Hypertension (Flolan/Veletri)	Flolan Veletri	Generic epoprostenol
 Rituximab Non-Hodgkin's lymphoma Chronic lymphocytic leukemia Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) 	Riabni	Rituxan Rituxan Hycela Ruxience Truxima

NJ-22-06-01 H6399_NR_30366_2022_C

Severe asthma	Cinqair	Fasenra Nucala Xolair
Viscosupplements (single injection)** • Osteoarthritis	Durolane Gel-One Monovisc	Synvisc-One
Viscosupplements (multiple injections)** • Osteoarthritis **Viscosupplements are one category. Use any preferred product before a non-preferred single or multiple injection viscosupplement.	Euflexxa Gelsyn-3 GenVisc Hyalgan Hymovis Supartz FX TriVisc Visco-3	Orthovisc Synvisc

For the following classes, preferred products may be covered under the Part D (pharmacy) benefit:

Drug Class	Non-preferred Product(s)	Preferred Product(s)
Bone Resorption Inhibitors • Osteoporosis	Evenity	Forteo
Immunologics • Crohn's disease	Actemra Avsola	Humira
ImmunologicsAnkylosing spondylitisJuvenile idiopathic arthritis	Cimzia Ilumya Inflectra	Enbrel Humira Xeljanz/Xeljanz XR
Immunologics • Plaque psoriasis	Orencia Remicade Renflexis Riabni Rituxan Ruxience Simponi Aria Stelara Tremfya Truxima	Enbrel Humira Otezla Skyrizi
Immunologics • Psoriatic arthritis		Enbrel Humira Otezla Rinvoq Skyrizi Xeljanz/Xeljanz XR
Immunologics • Rheumatoid arthritis	Tysabri	Enbrel Humira Rinvoq Xeljanz/Xeljanz XR

Multiple Sclerosis (relapsing forms)	Ocrevus	Kesimpta
 Clinically isolated syndrome 		
 Relapsing-remitting disease 		
Active secondary progressive disease		
PCSK9 inhibitors	Leqvio	Praluent*
 Lowering of LDL cholesterol 		
*Repatha is also a preferred product on open formularies		

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. For specific medical indications subject to step therapy, please see the corresponding clinical policy bulletin on the Aetna website.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Aetna. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

Aetna Assure Premier Plus (HMO D-SNP) is a Fully Integrated Dual Eligible Special Needs Plan with a Medicare contract and a contract with the New Jersey Medicaid program. Enrollment in Aetna Assure Premier Plus depends on contract renewal.

The formulary and/or pharmacy network may change at any time. You will receive notice when necessary. ©2022 Aetna Inc.

Aetna Assure Premier Plus (HMO D-SNP) is a Fully Integrated Dual Eligible Special Needs Plan with a Medicare contract and a contract with the New Jersey Medicaid program. Enrollment in Aetna Assure Premier Plus depends on contract renewal.

See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations, and conditions of coverage.

If you speak a language other than English, free language assistance services are available. Visit our website at **AetnaBetterHealth.com/New-Jersey-hmosnp** or call **1-844-362-0934 (TTY: 711)**, 8 AM to 8 PM, 7 days a week.

ESPAÑOL (SPANISH): Si habla un idioma que no sea el inglés, los servicios gratuitos de asistencia en idiomas están disponibles. Visite nuestro sitio web en AetnaBetterHealth.com/New-Jersey-hmosnp o llame al **1-844-362-0934 (TTY: 711)**, de 8 AM a 8 PM, los 7 días de la semana.

(CHINESE)傳統漢語(中文)如果您講英語以外的語言,則提供免費語言援助服務。

請造訪我們的網站 AetnaBetterHealth.com/New-Jersey-hmosnp 或致電, 1-844-362-0934(TTY:711),上午 8 時至下午 8 時,每週 7 天

You can get this document for free in other formats, such as large print, braille, or audio. Call Member Services at **1-844-362-0934 (TTY: 711)**, 8 AM to 8 PM, 7 days a week. The call is free.